Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct;38(5):937-945.
doi: 10.1007/s10557-023-07452-1. Epub 2023 Apr 13.

Recurrent Atherosclerotic Cardiovascular Disease Events Potentially Prevented with Guideline-Recommended Cholesterol-Lowering Therapy following Myocardial Infarction

Swati Sakhuja  1 , Vera A Bittner  2 , Todd M Brown  2 , Michael E Farkouh  3 , Emily B Levitan  4 , Monika M Safford  5 , Mark Woodward  6   7 , Ligong Chen  4 , Ruoyan Sun  8 , Nafeesa Dhalwani  9 , Jenna Jones  9 , Bethany Kalich  10 , Jason Exter  10 , Paul Muntner  4 , Robert S Rosenson  11 , Lisandro D Colantonio  4
Affiliations

Recurrent Atherosclerotic Cardiovascular Disease Events Potentially Prevented with Guideline-Recommended Cholesterol-Lowering Therapy following Myocardial Infarction

Swati Sakhuja et al. Cardiovasc Drugs Ther. 2024 Oct.

Abstract

Purpose: Many adults with atherosclerotic cardiovascular disease (ASCVD) who are recommended to take a statin, ezetimibe and/or a proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) by the 2018 American Heart Association/American College of Cardiology cholesterol guideline do not receive these medications. We estimated the percentage of recurrent ASCVD events potentially prevented with guideline-recommended cholesterol-lowering therapy following a myocardial infarction (MI) hospitalization.

Methods: We conducted simulations using data from US adults with government health insurance through Medicare or commercial health insurance in the MarketScan database. We used data from patients with an MI hospitalization in 2018-2019 to estimate the percentage receiving guideline-recommended therapy. We used data from patients with an MI hospitalization in 2013-2016 to estimate the 3-year cumulative incidence of recurrent ASCVD events (i.e., MI, coronary revascularization or ischemic stroke). The low-density lipoprotein cholesterol (LDL-C) reduction with guideline-recommended therapy was derived from trials of statins, ezetimibe and PCSK9i, and the associated ASCVD risk reduction was estimated from a meta-analysis by the Cholesterol-Lowering Treatment Trialists Collaboration.

Results: Among 279,395 patients with an MI hospitalization in 2018-2019 (mean age 75 years, mean LDL-C 92 mg/dL), 27.3% were receiving guideline-recommended cholesterol-lowering therapy. With current cholesterol-lowering therapy use, 25.3% (95%CI: 25.2%-25.4%) of patients had an ASCVD event over 3 years. If all patients were to receive guideline-recommended therapy, 19.8% (95%CI: 19.5%-19.9%) were estimated to have an ASCVD event over 3 years, representing a 21.6% (95%CI: 20.5%-23.6%) relative risk reduction.

Conclusion: Implementation of guideline-recommended cholesterol-lowering therapy could prevent a substantial percentage of recurrent ASCVD events.

Keywords: Guideline recommended cholesterol-lowering therapy; Low-density lipoprotein cholesterol; Myocardial infarction; Recurrent atherosclerotic cardiovascular disease; Secondary prevention.

PubMed Disclaimer

References

    1. Li S, Peng Y, Wang X, et al. Cardiovascular events and death after myocardial infarction or ischemic stroke in an older Medicare population. Clin Cardiol. 2019;42(3):391–9. - DOI - PubMed - PMC
    1. Jernberg T, Hasvold P, Henriksson M, et al. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. Eur Heart J. 2015;36(19):1163–70. - DOI - PubMed
    1. Grundy SM, Stone NJ, Bailey AL, et al. 2018 Guideline on the Management of Blood Cholesterol. J Amer Coll Cardiol. 2019;73(24):e285–350. - DOI
    1. Abdallah MS, Kosiborod M, Tang F, et al. Patterns and predictors of intensive statin therapy among patients with diabetes mellitus after acute myocardial infarction. Am J Cardiol. 2014;113(8):1267–72. - DOI - PubMed - PMC
    1. Karalis DG, Mallya UG, Ghannam AF, et al. Prescribing Patterns of Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors in Eligible Patients With Clinical Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia. Am J Cardiol. 2018;121(10):1155–61. - DOI - PubMed

MeSH terms